Table 3.

Disease status and evidence of infection at time of death

		Levofloxacin group	Placebo group
Deaths within 12 weeks
Disease status at death
	Myeloma in remission or responding	2/8 (25%)	10/22 (45%)
	Myeloma active—progressing	2/8 (25%)	5/22 (23%)
	Myeloma active—unknown	4/8 (50%)	7/22 (32%)
Evidence of infection
	No	5/8 (63%)	14/22 (64%)
	Yes	3/8 (37%)	8/22 (36%)
Deaths between 12 weeks and 52 weeks
Disease status at death
	Myeloma in remission or responding	5/32 (16%)	7/17 (41%)
	Myeloma active—progressing	27/32 (84%)	10/17 (59%)
Evidence of infection
	No	20/32 (63%)	10/17 (59%)
	Yes	12/32 (37%)	7/17 (41%)
Deaths between 0 weeks and 52 weeks
Disease status at death
	Myeloma in remission or responding	7/40 (17%)	17/39 (44%)
	Myeloma active—progressing	29/40 (73%)	15/39 (38%)
	Myeloma active—unknown	4/40 (10%)	7/39 (18%)
Evidence of infection
	No	25/40 (63%)	24/39 (62%)
	Yes	15/40 (37%)	15/39 (38%)

Data are n/N (%).